Welcome to our dedicated page for Cassava Sciences SEC filings (Ticker: SAVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cassava Sciences’ quest to treat Alzheimer’s produces dense scientific disclosures that can leave even seasoned investors hunting for answers. Finding trial updates, cash-runway details, or spotting when executives buy more shares often means combing through hundreds of pages and multiple form types.
Stock Titan turns that problem on its head. Our AI parses every Cassava Sciences annual report 10-K simplified, highlights clinical milestones inside each quarterly earnings report 10-Q filing, and flags Cassava Sciences Form 4 insider transactions real-time—minutes after they reach EDGAR. Whether you are asking “How do I read Cassava Sciences’ 10-K?” or searching for “Cassava Sciences proxy statement executive compensation,” the answers surface instantly in plain English summaries.
Coverage spans every filing: 8-K material events explained for trial results, S-3 shelf registrations that hint at future capital raises, and the definitive proxy where stock-based pay is outlined. Investors track:
- R&D spending trends without wading through accounting footnotes
- Cash-burn projections derived from Cassava Sciences earnings report filing analysis
- Phase 3 timeline disclosures within risk-factor sections
- Cassava Sciences executive stock transactions Form 4 that signal insider confidence
Still comparing data manually? With understanding Cassava Sciences SEC documents with AI, you can monitor “Cassava Sciences insider trading Form 4 transactions,” set alerts for each new Cassava Sciences 8-K, and get Cassava Sciences SEC filings explained simply—so you spend time making decisions, not decoding jargon.
Cassava Sciences reported a net loss of $44.2 million for the quarter and $67.6 million for the six months ended June 30, 2025, driven by $40.3 million of general and administrative expense and $5.1 million of research and development expense in the quarter. Cash and cash equivalents totaled $112.4 million, down from $128.6 million at year-end 2024, while total assets fell to $135.4 million and stockholders' equity declined to $88.0 million. Accounts payable and accrued expenses increased materially to $42.8 million, contributing to total liabilities of $47.4 million.
The company recorded $35.25 million of litigation loss contingencies as of June 30, 2025, including a $31.25 million reserve related to the consolidated securities action and a $4.0 million reserve related to an anti-SLAPP matter. Cassava paid a $40 million civil penalty to settle an SEC enforcement matter in 2024 and continues to cooperate with DOJ inquiries. Management states working capital is sufficient for at least the next 12 months. Operationally, the company completed the phase-out of its Alzheimer’s program in Q2 2025, entered a Yale license for simufilam in TSC-related epilepsy with up to $4.5 million in milestones plus tiered royalties, and announced positive preclinical TSC results showing a dose-related reduction in seizures in a mouse model.
Cassava Sciences (SAVA) filed an 8-K to disclose positive preclinical data for simufilam in tuberous sclerosis complex (TSC)-related epilepsy. In a Tsc1 conditional knockout mouse model that develops spontaneous seizures, multiple doses of simufilam were tested over ~3 weeks. The compound significantly reduced seizure progression in a dose-dependent manner; other measured endpoints did not reach significance.
The study was run with the TSC Alliance and PsychoGenics under the TSC Preclinical Consortium. Management plans to present full data at a scientific meeting and initiate the first human proof-of-concept trial in H1 2026. No financial terms, revenue impact, or guidance were provided. Item 7.01 makes the accompanying press release furnished, not filed.
Key takeaways:
- Preclinical efficacy signal supports simufilam’s mechanism beyond Alzheimer’s.
- Expands pipeline into rare-disease epilepsy market.
- Tight timeline sets a near-term catalyst but still carries high development risk.
FAQ
What is the current stock price of Cassava Sciences (SAVA)?
What is the market cap of Cassava Sciences (SAVA)?
